In early trial, an ancient drug shows promise against severe
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
SARS CoV 2 infection has evolved into a global pandemic. Low-dose colchicine combines anti-inflammatory action with a favorable safety profile.

This study aimed to evaluate the effect of treatment with colchicine on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with COVID-19.

In this prospective, open-label, randomized clinical trial (the Greek Study in the Effects of Colchicine in COVID-19 Complications Prevention), 105 patients hospitalized with COVID-19 were randomized in a 1:1 allocation to either standard medical treatment or colchicine with standard medical treatment.

Results:
-- A total of 105 patients were evaluated with 50 randomized to the control group and 55 to the colchicine group.
-- Median peak high-sensitivity cardiac troponin values were 0.0112 ng/mL in the control group and 0.008 ng/mL in the colchicine group.
-- Median maximum C-reactive protein levels were 4.5 mg/dL vs 3.1 mg/dL, respectively.
-- The clinical primary end point rate was 14.0% in the control group and 1.8% in the colchicine group.
-- Mean event-free survival time was 18.6 days the in the control group vs 20.7 in the colchicine group.
-- Adverse events were similar in the 2 groups, except for diarrhea, which was more frequent with colchicine group than the control group.

Conclusively, In this randomized clinical trial, participants who received colchicine had statistically significantly improved time to clinical deterioration. There were no significant differences in high-sensitivity cardiac troponin or C-reactive protein levels. These findings should be interpreted with caution.

Source: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2767593
H●●●●●●●a I●●r and 6 others like this6 shares
Like
Comment
Share
Dr. D●●●●●●s T●●●●s
Dr. D●●●●●●s T●●●●s Pathology
So far there no effective treatment for COVID19, the only alternative is to administer convalescent plasma with symptomatic treatment, the only life saving measure. The present experiments are not saving lives.
Jun 27, 2020Like
H●●●●●●●a I●●r
H●●●●●●●a I●●r General Medicine
Colchicine is used to treat Gout right?
Jun 27, 2020Like1